ImmunoGen's Elahere shows promise in treating ovarian cancer, stock surges.

ImmunoGen's ovarian cancer drug, Elahere, demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival compared to chemotherapy for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer patients who have received therapy. The company plans to submit an MAA to the European Medicines Agency and an sBLA to the FDA in the second half of this year. As a result, ImmunoGen's stock soared by 112.46%.